(3R,20R,24R,28S,34Z,36S,38R,41S)-N-(Cyclopropylsulfonyl)-9-methoxy-26,40,42-trioxo-4,25-dioxa-1,6,13,27,39-pentaazaheptacyclo(26.13.1.1(sup 3,41).0(sup 5,14).0(sup 7,12).0(sup 20,24).0(sup 36,38))tritetraconta-5,7,9,11,13,34-hexaene-38-carboxamide
MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).